Ibrutinib
Back to search| Scientific Name: | Ibrutinib |
| Brand Name: | Imbruvica |
| Company Owner: | Not Available |
| Mechanism Of Action | Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK) . It forms a covalent bond with a cysteine residue in the active site of BTK (Cys481) , leading to its inhibition. The inhibition of BTK plays a role in the B-cell receptor signaling and thus, the presence of ibrutinib prevents the phosphorylation of downstream substrates such as PLC-γ. |
| Description of the Drug: | Ibrutinib is an antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s Macroglobulinemia. |
| Protein Data Bank: |
Source: DrugBank Online – DrugBank.com. Retrieved 2023-01-23 from https://go.drugbank.com/drugs/DB09053
